企業プロフィール
Petros Pharmaceuticals 株価・ニュース・カタリスト
- ティッカー:
- PTPI
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
0.00 USD (-51.47%)
終値
最終更新: 2026年10月1日
—
時価総額
株価変動の要因
2026年10月1日 時点で PTPI は 51.5% 下落し、$0.0033 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Rx-to-OTC Technology Developer
Petros Pharmaceuticals is developing technology intended to help prescription medicines transition to nonprescription use. The company has exited its former commercial pharmaceutical and men's-health device businesses.
Software-as-a-Service Platform
The planned platform is intended to help pharmaceutical companies design and operate consumer-facing processes required for prescription-to-over-the-counter switches. Potential functions include education, self-selection, eligibility logic, and commercialization support.
Consumer Decision Interface
Petros is also developing a potential Software as a Medical Device component that would guide consumers through appropriate self-selection or deselection. The interface is intended to reduce subjectivity through clinically established decision logic.
ACNU Regulatory Framework
The strategy is aligned with the FDA's framework for nonprescription drug products with an additional condition for nonprescription use. Under this model, technology can help consumers use a medicine safely when the drug label alone is insufficient.
Discontinued Legacy Operations
Petros no longer commercializes STENDRA and has assigned the assets of its former vacuum-erection-device businesses to a third party. The company therefore operates as an early-stage technology developer rather than a current product marketer.
今後のカタリスト
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。